{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-030297","form_type":"8-K","ticker":"AVR","cik":"0002011514","company_name":"Anteris Technologies Global Corp.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.809216+00:00","generated_at":"2026-05-17T14:55:46.484771+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Anteris Technologies reports Q2 2025 net loss $42.7M; cash $28.4M; 130 DurAVR implants","bullets":["Revenue from ordinary activities $1.17M for six months, down 16% YoY; net loss $42.7M, up 22% YoY.","130 patients implanted with DurAVR THV since start; 21 in Q2 2025; 79 clinical sites qualified for PARADIGM trial.","R&D expenses $16.3M in Q2 on PARADIGM trial preparation and manufacturing scale-up.","Cash and equivalents $28.4M at June 30, 2025; net operating cash outflow $41.0M in H1 2025.","No dividend declared; board appointed two new directors David Roberts and Gregory Moss."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-030297","json":"https://secwatch.observer/filing/0001140361-25-030297.json","markdown":"https://secwatch.observer/filing/0001140361-25-030297.md","text":"https://secwatch.observer/filing/0001140361-25-030297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2011514/000114036125030297/0001140361-25-030297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2011514/000114036125030297/ef20053645_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:55:46.484771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}